A detailed history of Vista Investment Management transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Vista Investment Management holds 1,672 shares of VRTX stock, worth $840,096. This represents 0.33% of its overall portfolio holdings.

Number of Shares
1,672
Previous 1,700 1.65%
Holding current value
$840,096
Previous $710,000 10.28%
% of portfolio
0.33%
Previous 0.3%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$392.81 - $485.53 $10,998 - $13,594
-28 Reduced 1.65%
1,672 $783,000
Q1 2024

May 15, 2024

SELL
$407.69 - $446.08 $21,607 - $23,642
-53 Reduced 3.02%
1,700 $710,000
Q4 2023

Feb 14, 2024

BUY
$343.0 - $410.68 $343 - $410
1 Added 0.06%
1,753 $713,000
Q3 2023

Nov 13, 2023

SELL
$338.18 - $362.46 $8,116 - $8,699
-24 Reduced 1.35%
1,752 $609,000
Q2 2023

Aug 14, 2023

SELL
$314.42 - $351.91 $34,586 - $38,710
-110 Reduced 5.83%
1,776 $624,000
Q1 2023

May 15, 2023

BUY
$283.23 - $323.1 $10,762 - $12,277
38 Added 2.06%
1,886 $594,000
Q4 2022

Feb 13, 2023

SELL
$285.76 - $321.48 $2,571 - $2,893
-9 Reduced 0.48%
1,848 $533,000
Q3 2022

Nov 14, 2022

SELL
$273.83 - $305.53 $5,202 - $5,805
-19 Reduced 1.01%
1,857 $538,000
Q2 2022

Aug 12, 2022

SELL
$234.96 - $292.55 $5,169 - $6,436
-22 Reduced 1.16%
1,876 $529,000
Q1 2022

May 13, 2022

SELL
$221.42 - $260.97 $885 - $1,043
-4 Reduced 0.21%
1,898 $495,000
Q4 2021

Feb 14, 2022

SELL
$177.01 - $223.45 $4,602 - $5,809
-26 Reduced 1.35%
1,902 $418,000
Q3 2021

Nov 15, 2021

BUY
$181.39 - $202.99 $49,156 - $55,010
271 Added 16.35%
1,928 $350,000
Q2 2021

Aug 16, 2021

BUY
$187.49 - $221.1 $310,670 - $366,362
1,657 New
1,657 $334,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $129B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Vista Investment Management Portfolio

Follow Vista Investment Management and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vista Investment Management, based on Form 13F filings with the SEC.

News

Stay updated on Vista Investment Management with notifications on news.